Deciphera Pharmaceuticals Management
Management Kriterienprüfungen 3/4
Deciphera Pharmaceuticals' CEO is Steve Hoerter, appointed in Mar 2019, has a tenure of 5.25 years. total yearly compensation is $6.01M, comprised of 12.3% salary and 87.7% bonuses, including company stock and options. directly owns 0.084% of the company’s shares, worth $1.86M. The average tenure of the management team and the board of directors is 4.3 years and 9 years respectively.
Wichtige Informationen
Steve Hoerter
Geschäftsführender
US$6.0m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 12.3% |
| Amtszeit als Geschäftsführer | 5.3yrs |
| Eigentum des Geschäftsführers | 0.08% |
| Durchschnittliche Amtszeit des Managements | 4.3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 9yrs |
Jüngste Management Updates
Recent updates
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up
Apr 30
Diving Into Deciphera Pharmaceuticals
Apr 26We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Mar 13We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 02Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?
Sep 25Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Jul 26Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Jun 22Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S
May 08We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Apr 10We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 29Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside
Aug 29Deciphera Pharmaceuticals Q2 2022 Earnings Preview
Aug 03We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully
Jul 29Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now
Feb 11Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
Nov 22Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Aug 26Deciphera Pharmaceuticals posts data from cancer studies at ASCO21
Jun 04Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
May 10Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$190m |
| Dec 31 2023 | US$6m | US$738k | -US$195m |
| Sep 30 2023 | n/a | n/a | -US$194m |
| Jun 30 2023 | n/a | n/a | -US$187m |
| Mar 31 2023 | n/a | n/a | -US$182m |
| Dec 31 2022 | US$4m | US$703k | -US$179m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$258m |
| Mar 31 2022 | n/a | n/a | -US$286m |
| Dec 31 2021 | US$9m | US$676k | -US$300m |
| Sep 30 2021 | n/a | n/a | -US$274m |
| Jun 30 2021 | n/a | n/a | -US$258m |
| Mar 31 2021 | n/a | n/a | -US$255m |
| Dec 31 2020 | US$8m | US$650k | -US$266m |
| Sep 30 2020 | n/a | n/a | -US$271m |
| Jun 30 2020 | n/a | n/a | -US$263m |
| Mar 31 2020 | n/a | n/a | -US$218m |
| Dec 31 2019 | US$9m | US$435k | -US$192m |
| Sep 30 2019 | n/a | n/a | -US$157m |
| Jun 30 2019 | n/a | n/a | -US$126m |
| Mar 31 2019 | n/a | n/a | -US$126m |
| Dec 31 2018 | US$447k | n/a | -US$100m |
Vergütung im Vergleich zum Markt: Steve's total compensation ($USD6.01M) is about average for companies of similar size in the US market ($USD5.66M).
Entschädigung vs. Einkommen: Steve's compensation has increased whilst the company is unprofitable.
Geschäftsführer
Steve Hoerter (53 yo)
5.3yrs
Amtszeit
US$6,010,712
Vergütung
Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 5.3yrs | US$6.01m | 0.084% $ 1.9m | |
| Executive VP | 9.3yrs | US$2.03m | 0.049% $ 1.1m | |
| Executive VP & Chief Scientific Officer | less than a year | US$3.06m | 0% $ 0 | |
| Senior VP & Chief Commercial Officer | 5.8yrs | US$1.58m | 0.036% $ 801.7k | |
| Executive VP & Chief Medical Officer | 4.7yrs | US$2.13m | 0.084% $ 1.8m | |
| Senior VP & Chief Technical Officer | less than a year | keine Daten | keine Daten | |
| Senior Vice President of Finance & Investor Relations | no data | keine Daten | keine Daten | |
| Senior VP & General Counsel | 5.3yrs | keine Daten | keine Daten | |
| Senior VP & Chief Human Resources Officer | 2.4yrs | keine Daten | keine Daten | |
| Senior VP & Chief Development Officer | 4.3yrs | keine Daten | 0.040% $ 876.3k | |
| Senior VP & Head of International | 3.3yrs | keine Daten | keine Daten | |
| Senior Vice President of Clinical Development | 3.4yrs | keine Daten | keine Daten |
4.3yrs
Durchschnittliche Betriebszugehörigkeit
53yo
Durchschnittliches Alter
Erfahrenes Management: DCPH's management team is considered experienced (4.3 years average tenure).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 6.1yrs | US$6.01m | 0.084% $ 1.9m | |
| Independent Director | 9.3yrs | US$388.59k | 0% $ 0 | |
| Independent Director | 7.7yrs | US$396.09k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$398.55k | 0% $ 0 | |
| Independent Chairman | 4.5yrs | US$403.30k | 0% $ 0 | |
| Member of Scientific Advisory Board | 9yrs | keine Daten | keine Daten | |
| Independent Director | 16.8yrs | US$414.77k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 9yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 9yrs | keine Daten | keine Daten | |
| Independent Director | 9.3yrs | US$386.05k | 0.013% $ 281.5k | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten |
9.0yrs
Durchschnittliche Betriebszugehörigkeit
62yo
Durchschnittliches Alter
Erfahrener Vorstand: DCPH's board of directors are considered experienced (9 years average tenure).